Top

Published in:

01-04-2014 | Review

Updates in the management of high-grade glioma

Authors: David Bradley, Jeremy Rees

Published in: Journal of Neurology | Issue 4/2014

Abstract

The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.

Stupp R, Mason WP, van den Bent MJ, Weller M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMed

Malmstrom A, Gronberg BH, Marosi C, Stupp R et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926CrossRefPubMed

Wick W, Platten M, Meisner C, Felsberg J et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707–715CrossRefPubMed

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342CrossRefPubMed

Yang JC, Haworth L, Sherry RM, Hwu P et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434PubMedCentralCrossRefPubMed

Miller K, Wang M, Gralow J, Dickler M et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676CrossRefPubMed

10.

Tuettenberg J, Friedel C, Vajkoczy P (2006) Angiogenesis in malignant glioma—a target for antitumor therapy? Crit Rev Oncol Hematol 59(3):181–193CrossRefPubMed

11.

Kreisl TN, Kim L, Moore K, Duic P et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745PubMedCentralCrossRefPubMed

12.

Cai LB, Li J, Lai MY, Shan CG et al (2013) Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma. Chin J Cancer Res 25(2):206–211PubMedCentralPubMed

13.

Gil MJ, de Las Penas R, Reynes G, Balana C et al (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs 23(6):659–665CrossRefPubMed

14.

Vauleon E, Mesbah H, Gedouin D, Lecouillard I et al (2012) Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab. Bull Cancer 99(2):121–126PubMed

15.

Cecchi M, Vaiani M, Ceroti M, Banfi R (2013) A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma. Int J Clin Pharm 25(3):483–487CrossRef

16.

Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 91(3):359–367CrossRefPubMed

17.

Desjardins A, Reardon DA, Coan A, Marcello J et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118(5):1302–1312CrossRefPubMed

18.

Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14(21):7068–7073PubMedCentralCrossRefPubMed

19.

Friedman HS, Prados MD, Wen PY, Mikkelsen T et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740CrossRefPubMed

20.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B et al (2013) Phase II study of Bevacizumab and Temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 33(4):1657–1660PubMed

21.

Nagane M, Nishikawa R, Narita Y, Kobayashi H et al (2012) Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 42(10):887–895PubMedCentralCrossRefPubMed

22.

Nagpal S, Harsh G, Recht L (2011) Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemother Res Pract 2011:602812PubMedCentralPubMed

23.

Narayana A, Kelly P, Golfinos J, Parker E et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110(1):173–180CrossRefPubMed

24.

Nghiemphu PL, Liu W, Lee Y, Than T et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14):1217–1222PubMedCentralCrossRefPubMed

25.

Norden AD, Young GS, Setayesh K, Muzikansky A et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787CrossRefPubMed

26.

Quant EC, Norden AD, Drappatz J, Muzikansky A et al (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550–555PubMedCentralCrossRefPubMed

27.

Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22):5297–5305CrossRefPubMed

28.

Reardon DA, Desjardins A, Peters KB, Gururangan S et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164PubMedCentralCrossRefPubMed

29.

Ruiz-Sanchez D, Calero MA, Sastre-Heres AJ, Garcia MT et al (2012) Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: comparison with other second-line treatments without this regimen. Oncol Lett 4(5):1114–1118PubMedCentralPubMed

30.

Sahebjam S, Garoufalis E, Guiot MC, Muanza T et al (2013) Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Can J Neurol Sci 40(2):241–246CrossRefPubMed

31.

Seystahl K, Wiestler B, Hundsberger T, Happold C et al (2013) Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 69(2):95–101CrossRefPubMed

32.

Taillibert S, Vincent LA, Granger B, Marie Y et al (2009) Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72(18):1601–1606CrossRefPubMed

33.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259CrossRefPubMed

34.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729CrossRefPubMed

35.

Zuniga RM, Torcuator R, Jain R, Anderson J et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91(3):329–336CrossRefPubMed

36.

Wong ET, Gautam S, Malchow C, Lun M et al (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw 9(4):403–407

37.

Zhang G, Huang S, Wang Z (2012) A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci 19(12):1636–1640CrossRefPubMed

38.

Shields LB, Kadner R, Vitaz TW, Spalding AC (2013) Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Radiat Oncol 8(1):101PubMedCentralCrossRefPubMed

39.

Chinot O, Wick W, Mason W, Henriksson R et al (2012) Phase III trial of bevacizumab added to standard radiotherapy and temozolamide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGLIO. Neuro Oncol 14(suppl 6):OT–03

40.

Gilbert MR, Dignam J, Won M, Blumenthal DT et al (2013) Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31(suppl):abstr 1

41.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479CrossRefPubMed

42.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24(18):2715–2722CrossRefPubMed

43.

Cairncross G, Berkey B, Shaw E, Jenkins R et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24(18):2707–2714CrossRefPubMed

44.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350CrossRefPubMed

45.

Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343PubMedCentralCrossRefPubMed

Title: Updates in the management of high-grade glioma
Authors: David Bradley
Jeremy Rees
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 4/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-7032-x

At a glance: The STEP trials

Springer Medicine

Updates in the management of high-grade glioma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

A follow-up 18F-FDG brain PET study in a case of Hashimoto's encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis

Selective retinal ganglion cell loss in familial dysautonomia

Sir Francis Walshe (1885–1973)

Recent advances in epilepsy

A case of steroid-responsive MADSAM with late appearance of a partial conduction block in the forearm